The clinical trial, sponsored by the University of Texas Southwestern Medical Center, investigates the relationship between amnestic mild cognitive impairment (aMCI) and mild traumatic brain injury (mTBI) using HD-tDCS. Given the increasing prevalence of cognitive disorders in aging populations, this study addresses a significant unmet medical need. The findings could inform future therapeutic strategies and biomarker development, potentially positioning the sponsor as a leader in cognitive impairment research. The market for cognitive enhancement and neurostimulation devices is growing, with increasing interest from both pharmaceutical and medical device companies. Competitive implications include the potential for partnerships or acquisitions based on successful outcomes, particularly if the study identifies novel biomarkers or effective interventions.